GENEVA, Dec 22 — Swiss pharmaceutical giant Novartis said today it was to acquire a UK-based biotech company developing gene therapies for eye diseases called Gyroscope Therapeutics.
Novartis will make an upfront payment of US$800 million to acquire all of the outstanding share capital of the company, as well as potential additional milestone payments of up to US$700 million, it said in a statement. Gyroscope Therapeutics has been developing a one-time gene therapy to treat an age-related condition known as geographic atrophy, which causes lesions on the retina and can cause blindness, it said.Novartis said the transaction’s closing was still subject to regulatory approvals. — AFP
Россия Последние новости, Россия Последние новости
Similar News:Вы также можете прочитать подобные новости, которые мы собрали из других источников новостей
Источник: malaymail - 🏆 1. / 86 Прочитайте больше »